Effects of intrathecal capsaicin and an NK-1 antagonist, CP,96-345, on the thermal hyperalgesia observed following unilateral constriction of the sciatic nerve in the rat.
We evaluated the effect of intrathecal (i.t.) capsaicin (CAP) and the NK-1 selective non-peptidic antagonist, CP,96-345, on the thermal hyperalgesia ordinarily observed after unilateral partial ligation of the sciatic nerve in rats. CAP was injected i.t. 2 days after constriction injury. Seven days after partial ligation, the levels of substance P (sP), calcitonin gene-related peptide (CGRP) and vasoactive intestinal polypeptide (VIP) were the same in the left and right dorsal horns of the lesioned rats which were injected with vehicle (VEH). CAP (75 micrograms/15 microliters of 20% 2-hydroxypropyl-beta-cyclodextrin) resulted in an equal reduction (40-50%) in the dorsal horn levels of sP and CGRP, but not VIP. After 7 days, i.t. CAP increased the paw withdrawal latency (PWL) of the non-injured hind paw. In contrast, there was no change in the PWL of the injured paw when compared to that of VEH-treated animals. Thus, CAP did not abolish the hyperalgesic state. We concluded that the thermal hyperalgesia after sciatic nerve constriction injury is not mediated by CAP-sensitive C fibers. CP,96-345 given i.t. at a dose which is physiologically active (400 micrograms) had little effect on the thermal response latency of either the normal or hyperesthetic paw. This provides further evidence that neither the normal pain response nor hyperalgesic state is dependent upon a dorsal horn action of sP.
Yamamoto
Tatsuo
T
Department of Anesthesiology (0818), University of California at San Diego, La Jolla, CA 92093-0818 USA.
Yaksh
Tony L
TL
D000818:Animals; D001713:Biphenyl Compounds / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D002211:Capsaicin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D006358:Hot Temperature; D006993:Hypnotics and Sedatives / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D007278:Injections, Spinal; D008297:Male; D015288:Neurokinin A / Q000037:antagonists & inhibitors*; D009479:Neuropeptides / Q000378:metabolism; D009619:Nociceptors / Q000187:drug effects / Q000502:physiology; D010146:Pain / Q000517:prevention & control*; D011863:Radioimmunoassay; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000378:metabolism / Q000502:physiology*; D013116:Spinal Cord / Q000378:metabolism
D001713:Biphenyl Compounds; D006993:Hypnotics and Sedatives; D009479:Neuropeptides; D015288:Neurokinin A; D002211:Capsaicin; C066892:CP 96345